Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Roche Holding AG News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,819.40 | 24.60 | 0.28% |
| CAC 40 | 7,995.41 | 83.88 | 1.06% |
| DAX 40 | 23,669.88 | 105.87 | 0.45% |
| Dow JONES (US) | 46,946.41 | 387.94 | 0.83% |
| FTSE 100 | 10,400.18 | 82.49 | 0.80% |
| HKSE | 25,868.54 | 402.94 | 1.58% |
| NASDAQ | 22,374.18 | 268.82 | 1.22% |
| Nikkei 225 | 53,700.39 | 119.22 | -0.22% |
| NZX 50 Index | 13,182.23 | 17.65 | 0.13% |
| S&P 500 | 6,699.38 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,614.30 | 38.70 | 0.45% |
| SSE Composite Index | 4,049.91 | 34.88 | -0.85% |